This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
It was called to our attention (JAMA178:46 [Oct. 21] 1961) that a misstatement had been made in a correction. In this notation Dr. Kushner commented on an article, Treatment of Reticulosis (JAMA175:84 [Jan. 14] 1961), wherein the dosage of aminopterin was incorrectly stated. We concur that this dosage is incorrect. However, Dr. Kushner is in error in stating that aminopterin has been taken off the market. Aminopterin is available for the treatment of acute leukemia in children, and we have no present intention of removing it from the market.Dr. Kushner, however, commits a misstatement which has caused considerable confusion in that he states "It so happens that amethopterin...." Dr. Kushner is referring to methotrexate. Methotrexate was formally known as amethopterin, but this name was discontinued because it is readily confused with aminopterin. Methotrexate has one, and only one, name. Methrotrexate is the
Swanzey EH. Dosage of Aminopterin. JAMA. 1962;179(6):470. doi:10.1001/jama.1962.03050060080020
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: